Arca Biopharma and Medtronic extend collaboration
WESTMINSTER — Arca Biopharma Inc. (Nasdaq: ABIO) and Medtronic (NYSE: MDT) have extended their U.S., Canadian and European Clinical Trial Collaboration Agreement for another year.
The agreement will now go until April 2019.
Under the collaboration, Medtronic has supported the clinical trial use of its continuous monitoring devices and managed analysis of patients’ cardiac rhythms. Arca Biopharma has been using Medtronic devices in its development of Gencaro, a beta-blocker for patients with chronic heart failure. Arca is applying precision medicine to developing genetically-targeted therapies for cardiovascular disease.
SPONSORED CONTENT
People Powered: Preparing Longmont Businesses for Economic Success
Longmont Chamber and FNBO present People Powered on April 24, 2024, aiming to inform business owners about workforce development, housing, and transportation issues.
WESTMINSTER — Arca Biopharma Inc. (Nasdaq: ABIO) and Medtronic (NYSE: MDT) have extended their U.S., Canadian and European Clinical Trial Collaboration Agreement for another year.
The agreement will now go until April 2019.
Under the collaboration, Medtronic has supported the clinical trial use of its continuous monitoring devices and managed analysis of patients’ cardiac rhythms. Arca Biopharma has been using Medtronic devices in its development of Gencaro, a beta-blocker for patients with chronic heart failure. Arca is applying precision medicine to developing genetically-targeted therapies for cardiovascular disease.
…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!
